Dashboard
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 7.77% and Operating profit at -205.39% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -198.85
Flat results in Sep 26
Risky - Negative EBITDA
Falling Participation by Institutional Investors
Stock DNA
Healthcare Services
INR 7,737 Cr (Small Cap)
NA (Loss Making)
40
0.00%
-0.73
-84.23%
17.31
Total Returns (Price + Dividend) 
Latest dividend: 0.09280814339455631 per share ex-dividend date: Feb-14-2019
Risk Adjusted Returns v/s 
Returns Beta
News

Suven Life Sciences Ltd is Rated Sell
Suven Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 13 November 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Suven Life Sciences Ltd is Rated Sell
Suven Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Suven Life Sciences Ltd is Rated Sell
Suven Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 October 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)
16-Nov-2026 | Source : BSEPlease find enclosed the Revised News Release of our company
Announcement under Regulation 30 (LODR)-Press Release / Media Release
16-Nov-2026 | Source : BSEPlease find enclosed the News Release of our Company
Announcement under Regulation 30 (LODR)-Press Release / Media Release
12-Nov-2026 | Source : BSEPlease find enclosed News Release of our Company
Corporate Actions 
No Upcoming Board Meetings
Suven Life Sciences Ltd has declared 150% dividend, ex-date: 14 Feb 19
Suven Life Sciences Ltd has announced 1:2 stock split, ex-date: 23 Mar 07
Suven Life Sciences Ltd has announced 1:1 bonus issue, ex-date: 23 Mar 07
Suven Life Sciences Ltd has announced 1:2 rights issue, ex-date: 17 Oct 22
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 6 Schemes (0.08%)
Held by 16 FIIs (0.46%)
Jasti Property And Equity Holdings Private Limited (in Its Capacity As Sole Trustee Of Jasti Family (64.93%)
Tejas Trivedi (1.34%)
24.85%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is -66.39% vs 134.87% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 16.20% vs -179.85% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -22.07% vs -47.81% in Sep 2024
Growth in half year ended Sep 2025 is -65.85% vs -111.26% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 7.90% vs -44.25% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -97.56% vs -48.73% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 6.76% vs -43.03% in Mar 2025
YoY Growth in year ended Mar 2026 is -71.91% vs -52.98% in Mar 2025